Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.